Literature DB >> 6095568

Fine needle aspiration biopsy of the liver. A study of 102 consecutive cases.

S Whitlatch, C Nuñez, D A Pitlik.   

Abstract

One hundred five CT-guided or ultrasound-guided fine needle aspirations of liver in 102 consecutive patients were reviewed. Adequate histologic confirmation or clinical follow-up of the final diagnosis was available for 86 of the 105 aspirations. A definite diagnosis of malignancy was made in 53 of the 61 aspirations performed on patients with malignant hepatic disease (86.9%). There were no false positives. The most common tumors detected were metastatic adenocarcinomas from an unknown primary or from the colon and rectum. The tumors were typed correctly in nearly all cases. Benign lesions encountered included cysts, abscesses, hemangiomas, cirrhosis and fatty metamorphosis. No serious complications were encountered as a result of aspiration. Guided fine needle aspiration biopsy of focal liver lesions appears to be an accurate, safe and relatively inexpensive method of diagnosis.

Entities:  

Mesh:

Year:  1984        PMID: 6095568

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  5 in total

Review 1.  Needle biopsy of the liver. A critique of four currently available methods.

Authors:  R R Babb; R J Jackman
Journal:  West J Med       Date:  1989-01

Review 2.  The changing face of hepatic resection.

Authors:  S Iwatsuki; D G Sheahan; T E Starzl
Journal:  Curr Probl Surg       Date:  1989-05       Impact factor: 1.909

3.  Fine needle biopsy: effect of needle size.

Authors:  F Mutch
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

4.  Non-imaging-guided fine-needle aspiration of liver lesions: a retrospective study of 279 patients.

Authors:  Yeouda Edoute; Ehud Malberger; Orly Tibon-Fishe; Nimer Assy
Journal:  World J Gastroenterol       Date:  1999-04       Impact factor: 5.742

5.  Fine needle aspiration biopsy of liver - an update.

Authors:  David C Chhieng
Journal:  World J Surg Oncol       Date:  2004-03-16       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.